Ralf Kronenwett

Title: Ralf Kronenwett: Innovator in Chemotherapy Prediction

Introduction

Ralf Kronenwett is a notable inventor based in Salt Lake City, UT (US). He has made significant contributions to the field of oncology through his innovative methods for predicting chemotherapy benefits. With a total of two patents to his name, Kronenwett's work is paving the way for more personalized cancer treatment.

Latest Patents

Kronenwett's latest patents focus on a method of using biomarkers and clinical variables for predicting chemotherapy benefit. These methods involve predicting chemotherapy benefit based on the expression analysis of biomarkers, such as RNA biomarker transcription analysis, taken from tumor samples. The biomarker expression data can be combined with clinical variables, including tumor size and nodal status, to generate a profile that predicts the benefit of including chemotherapy as a treatment decision.

Career Highlights

Throughout his career, Ralf Kronenwett has worked with prominent companies in the biotechnology sector, including Myriad Genetics, Inc. and Myriad International GmbH. His experience in these organizations has allowed him to develop and refine his innovative approaches to cancer treatment.

Collaborations

Kronenwett has collaborated with talented individuals in his field, including Alexander Gutin and Julia Reid. These partnerships have contributed to the advancement of his research and the successful development of his patented methods.

Conclusion

Ralf Kronenwett's contributions to the field of oncology through his innovative patents are significant. His work in predicting chemotherapy benefits is a testament to the importance of personalized medicine in cancer treatment.